Sleep research article

<i>Akkermansia muciniphila</i> protects diabetes-associated cognitive decline by enhancing leucine catabolism and suppressing neuronal excessive mitophagy.

2026-01-01 · arXiv: 10.1080/19490976.2026.2739666

Authors: Ye X , Cai Q , Li Y , You M , Chen J , Pan Y , Zhu M , Lu Z , Chen S , Lin Y , Zhang W , Liu X , Wang Z , Hong G , Wu W , Zheng H

One-line summary

A sleep science research article on <i>Akkermansia muciniphila</i> protects diabetes-associated cognitive decline by enhancing leucine catabolism and suppressing neuronal excessive mitophagy..

Sleep health notes

Sleep health notes will be added by the Sleepatch editorial team.

中文解读

中文解读待补充:本站会优先为失眠研究、睡眠质量改善、昼夜节律等高价值睡眠研究添加中文说明。

Original abstract

Dysregulation of the gut-brain metabolic axis has been implicated in the progression of diabetes-associated cognitive decline (DACD), yet its underlying mechanism remains largely unknown. Herein, we identified a low abundance of <i>Akkermansia muciniphila</i> (AKK) and high leucine levels as key driving factors of DACD in both diabetic mice and patients. Our results revealed that AKK bacteria hold the capacity to catabolize leucine, and the elevated leucine levels observed in diabetic mice and patients are partly attributed to a low abundance of AKK bacteria. Moreover, leucine supplementation and deprivation further confirmed that excessive leucine accelerated and aggravated the progression of DACD in mice. Mechanistically, leucine directly modulated the phosphorylation of TBK1 and, in turn, phosphorylated the autophagy adaptor OPTN, thereby enhancing its binding capacity to LC3 and Ub chains and triggering neuronal excessive mitophagy. Therefore, this study uncovers a new mechanism of the gut-brain metabolic axis involved in DACD progression and provides a novel perspective for gut-targeted therapy of cognitive disorders.

6.0App value
8.0Research quality
7.0Wellness relevance

Links and sources

⚕️ Medical Disclaimer
This content is provided for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Sleep disorders, chronic insomnia, sleep apnea, and other conditions must be evaluated and treated by a qualified healthcare professional. If you experience persistent or severe sleep problems, consult a licensed physician or sleep specialist. Research cited refers to peer-reviewed studies; individual results may vary. Sleepatch does not endorse any specific medication, supplement, or therapy.

Want a personalized sleep improvement plan?

Sleepatch can prepare a customized sleep wellness program, insomnia relief guide, and evidence-based sleep coaching based on your needs.

Explore sleep services

Comments

No comments yet. Be the first to share your thoughts on this sleep research.
Login or register to leave a comment